["{\n\"step_by_step_thinking\": \"The relevant documents discuss various treatments for Parkinson's disease. Dopaminergic agonists are discussed as a treatment option. Isradipine is not mentioned as a treatment option for Parkinson's disease in the provided documents. Calcium-entry blockers-induced parkinsonism is discussed, but it does not mention isradipine specifically. CQA 206-291 is investigated in a trial, but its outcome is that it will not be developed clinically due to laboratory-based toxicity concerns. Therefore, based on the information provided, we can conclude that isradipine's effectiveness for Parkinson's disease is not discussed.\",\n\"answer_choice\": \"B\"\n}"]